GUIDELINE-PREFERRED 1L TREATMENT FOR ALK+ NSCLC PATIENTS2,3
Superior survival1
OS rate: 62.5% with ALECENSA vs 45.5% with crizotinib; ALECENSA mOs yet to be reached
GUIDELINE-PREFERRED 1L TREATMENT FOR ALK+ NSCLC PATIENTS2,3
Proven efficacy1
mPFS 34.8 months with ALECENSA vs 10.9 months with crizotinib
GUIDELINE-PREFERRED 1L TREATMENT FOR ALK+ NSCLC PATIENTS2,3
Click here for more information about
how Roche is responding to COVID-19
Questions about our medicines? Visit
GUIDELINE-PREFERRED 1L TREATMENT FOR ALK+ NSCLC PATIENTS2,3
Superior survival1
OS rate: 62.5% with ALECENSA vs 45.5% with
crizotinib; ALECENSA mOS yet to be reached
Proven efficacy1
mPFS 34.8 months with ALECENSA
vs 10.9 months with crizotinib
Proven Protection
Nearly 3 years freedom from progression1
(34.8 months [95% Cl: 17.7, NE])
Fast facts
~70%
of patients have never smoked5–7
Fast facts
>50%
are younger than 50 years5,8
Fast facts
~30%
have baseline CNS metastases
at diagnosis9,10
Fast facts
>50%
of patients receiving crizotinib
progress within 1 year1
Fast facts
>50%
of patients receiving crizotinib
will not live past 5 years1
Fast Facts
~70% of patients have never smoked5-7
Fast Facts
>50% are younger than 50 years5-8
Fast Facts
>30% have baseline CNS metastases at diagnosis9,10
Fast Facts
~50% of patients receiving crizotinib progress within 1 year1
Fast Facts